NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
Clinical Trials
9 trialsNCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT05009992 2025-12-17
PNOC022
University of California, San Francisco
Phase 2 Recruiting
NCT05580562 2025-08-26
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT03416530 2025-02-14
ONC201 in Pediatric H3 K27M Gliomas
Jazz Pharmaceuticals
Phase 1 Terminated
NCT02525692 2024-12-24
Oral ONC201 in Adult Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT04629209 2023-11-24
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT04854044 2021-05-12
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn